
PaySign Inc (PAYS) Stock Forecast & Price Target
PaySign Inc (PAYS) Analyst Ratings
Bulls say
PaySign Inc. is projected to achieve a 27.5% increase in total revenue for Q2/24 compared to Q2/23, with pharmaceutical revenue significantly contributing approximately 18% to the total. The company's gross profit margins have improved by 280 basis points year-over-year, driven by the growing share of higher-margin pharma revenue, which highlighted a remarkable increase from 6% in Q1/23. Additionally, PaySign reported a substantial 135% rise in adjusted EBITDA to $1.7 million, with a notable increase in adjusted EBITDA margin of 560 basis points to 12.8%, reflecting strong operational performance and profitability growth.
Bears say
PaySign Inc. reported a decline in average revenue per plasma center, which fell from $8,041 in Q3/23 to $7,991 in Q3/24, despite a significant increase in patient affordability claim volume. The company also experienced a substantial drop in unrestricted cash, down to $7 million from $17 million at the end of 2023, primarily due to increased invoicing for patient affordability claims and related payables. Additionally, operational challenges, including center closures due to adverse weather and employment shortages, have further exacerbated the company's financial pressures.
This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.
PaySign Inc (PAYS) Analyst Forecast & Price Prediction
Start investing in PaySign Inc (PAYS)
Order type
Buy in
Order amount
Est. shares
0 shares